Amgen’s termination of brodalumab stuns psoriasis world
Posted on: 25/06/2015 - 14:06
VANCOUVER, B.C. – Amgen’s recent announcement that it is pulling the plug on further development of the investigational interleukin-17 receptor A inhibitor brodalumab was the red hot topic among...
Field of Interest: Rheumatology
Type: News Item